Pro-Dex, Inc. Announces Fiscal 2022 Second Quarter and Six-Month Results

Rhea-AI Summary

Pro-Dex, Inc. (NASDAQ:PDEX) reported a robust fiscal 2022 second quarter with net sales up 23% to $10.2 million, driven by orthopedic surgical handpiece sales. Gross profit rose 31% to $3.4 million, and operating expenses declined by 13% to $1.8 million. However, net income fell to $925,000 ($0.25 per diluted share) compared to $1.8 million ($0.44) from the same quarter last year. Looking ahead, Pro-Dex warns of supply chain challenges that could reduce net sales in the upcoming quarters but remains optimistic about long-term prospects.

Positive

• Net sales increased by 23% to $10.2 million for Q2 2022.
• Gross profit rose by 31% to $3.4 million in Q2 2022.
• Operating expenses decreased by 13% to $1.8 million.

Negative

• Net income fell to $925,000 ($0.25 per diluted share), down from $1.8 million ($0.44).
• Supply chain challenges are expected to negatively impact financial performance in Q3 and Q4 2022.

IRVINE, CA / ACCESSWIRE / February 3, 2022 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2022 second quarter ended December 31, 2021. The Company also filed its Quarterly Report on Form 10-Q for the second quarter of fiscal year 2022 with the Securities and Exchange Commission today.

Quarter Ended December 31, 2021

Net sales for the three months ended December 31, 2021, increased $1.9 million, or 23%, to $10.2 million from $8.3 million for the three months ended December 31, 2020, due primarily to sales of the orthopedic surgical handpiece that we sell to our largest customer.

Gross profit for the three months ended December 31, 2021, increased $808,000, or 31%, to $3.4 million from $2.6 million for the same period in fiscal 2021, due primarily to increased sales. We also had fewer COVID-19 related paid absences in our machine shop, assembly, and quality operations in the second quarter of fiscal 2022 compared to the same period of the prior fiscal year.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended December 31, 2021, decreased $273,000, or 13%, to $1.8 million compared to $2.1 million in the prior fiscal year's corresponding quarter, reflecting in part the higher number of billable engineering projects in the current fiscal quarter compared to the same period in the prior fiscal year.

Net income for the quarter ended December 31, 2021, was $925,000, or $0.25 per diluted share, compared to $1.8 million, or $0.44 per diluted share, for the corresponding quarter in fiscal 2021.

Six Months Ended December 31, 2021

Net sales for the six months ended December 31, 2021, increased $3.3 million, or 20%, to $20.2 million from $16.9 million for the six months ended December 31, 2020, due primarily to sales of the orthopedic surgical handpiece that we sell to our largest customer.

Gross profitfor the six months ended December 31, 2021,increased $761,000, or 13%, compared to the same period in fiscal 2021 due to the increase in sales described above.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the six months ended December 31, 2021, remained fairly flat compared to the prior fiscal year's corresponding period.

Net income for the six months ended December 31, 2021, was $2.0 million, or $0.52 per diluted share, compared to $2.9 million, or $0.72 per diluted share, for the corresponding period in fiscal 2021.

Guidance

Pro-Dex, Inc. typically does not provide sales, earnings, or other guidance, however, during calendar 2021, we began to see some challenges in our supply chain in the form of delayed shipments, longer lead times, and surcharges, much of which our suppliers indicate have been caused by the COVID-19 pandemic. During early calendar 2022, we are seeing these conditions persist and worsen such that we expect them to negatively impact our financial performance in the third quarter and possibly the fourth quarter of fiscal 2022, reflected as a reduction in net sales. We continue to implement plans and processes to mitigate these challenges that many manufacturers similarly face. Our long-term prospects remain positive and we believe these challenges will negatively impact us only in the short-term.

CEO Comments

Richard L. ("Rick") Van Kirk, the Company's President and Chief Executive Officer, commented, "We are pleased with our second quarter and year-to-date results especially because our net sales growth reflects a $40M annual run rate and we are encouraged by our strong operating income for the quarter." Mr. Van Kirk continued, "In addition, we have been engaged by several customers to provide various non-recurring engineering projects. To focus on these secured customer contracts, we have transferred resources from our internal research and development projects thus delaying the launch of our internal products."

The amount spent on internal projects under development as well as the estimated market launch date and estimated future annual revenue is summarized below (in thousands):

		Three and Six Months Ended December 31, 2021							Three and Six Months Ended December 31, 2020							Est Market Launch(1)				Est Annual Revenue
Total Research & Development costs:		$	615		$	1,596			$	989		$	2,080
Products in development:
ENT Shaver			32			263				76			258			Q4 2022				$	1,000
Vital Ventilator			-			108				8			65			Q1 2023				$	1,500
CMF Driver			-			-				279			468			(2)				$	1,000
Sustaining & Other			583			1,225				626			1,289
Total		$	615		$	1,596			$	989		$	2,080

1. Represents the calendar quarter of expected market launch. The internal projects currently under development have been delayed because we have been engaged by our customers to complete several billable non-recurring engineering projects.
2. The CMF Driver was completed in the third quarter of fiscal 2021 and began shipping to our existing largest customer under a distribution agreement we executed in the first quarter of fiscal 2021.

As we introduce new products into the market, we expect to see an increase in sustaining and other engineering expenses. Typical examples of sustaining engineering activities include, but are not limited to, end-of- life component replacement, especially in electronic components found in our printed circuit board assemblies, analysis of customer complaint data to improve process and design, replacement and enhancement of tooling and fixtures used in the machine shop, assembly operations, and inspection areas to improve efficiency and through-put. Additionally, these costs include development projects that may be in their infancy and may or may not result in a full-fledged product development effort.

About Pro-Dex, Inc.:

Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. Pro-Dex, Inc. also sells rotary air motors to a wide range of industries. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's website at www.pro-dex.com.

Statements herein concerning the Company's plans, growth, and strategies may include 'forward-looking statements' within the context of the federal securities laws. Statements regarding the Company's future events, developments, and future performance (including, but not limited to, estimated product launch dates and estimated future revenue), as well as management's expectations, beliefs, plans, estimates, or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission.

(tables follow)

PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except share amounts)

		December 31, 2021				June 30, 2021
ASSETS
Current Assets:
Cash and cash equivalents		$	5,252			$	3,721
Investments			1,241				1,295
Accounts receivable, net of allowance for doubtful accounts of $4 and $2 at December 31, 2021 and at June 30, 2021, respectively			8,850				10,933
Deferred costs			424				193
Inventory			9,285				8,437
Prepaid expenses and other current assets			1,036				434
Total current assets			26,088				25,013
Land and building, net			6,390				6,437
Equipment and leasehold improvements, net			4,605				3,845
Right-of-use asset, net			2,429				2,605
Intangibles, net			157				186
Deferred income taxes, net			463				463
Investments			1,940				1,704
Other assets			42				67
Total assets		$	42,114			$	40,320
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts payable		$	2,315			$	2,288
Accrued expenses			1,812				2,198
Deferred revenue			584				150
Note payable			1,260				1,236
Total current liabilities			5,971				5,872
Lease liability, net of current portion			2,248				2,432
Income taxes payable			991				397
Notes payable, net of current portion			10,899				11,535
Total non-current liabilities			14,138				14,364
Total liabilities			20,109				20,236
Shareholders' Equity:
Common shares; no par value; 50,000,000 shares authorized; 3,641,983 and 3,645,660 shares issued and outstanding at December 31, 2021 and June 30, 2021, respectively			7,886				7,953
Retained earnings			14,119				12,131
Total shareholders' equity			22,005				20,084
Total liabilities and shareholders' equity		$	42,114			$	40,320

PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
(In thousands, except per share amounts)

		Three Months Ended December 31,								Six Months Ended December 31,
		2021				2020				2021				2020
Net sales		$	10,173			$	8,265			$	20,161			$	16,855
Cost of sales			6,769				5,669				13,329				10,784
Gross profit			3,404				2,596				6,832				6,071
Operating expenses: Selling expenses			22				150				59				280
General and administrative expenses			1,165				936				2,257				1,641
Research and development costs			615				989				1,596				2,080
Total operating expenses			1,802				2,075				3,912				4,001
Operating income			1,602				521				2,920				2,070
Interest expense			(117	)			(75	)			(237	)			(129	)
Unrealized gain (loss) on marketable equity investments			(300	)			1,413				(152	)			1,306
Interest and other income			25				20				49				61
Gain on sale of investments			-				-				-				12
Income from operations before income taxes			1,210				1,879				2,580				3,320
Income tax expense			(285	)			(129	)			(592	)			(412	)
Net income		$	925			$	1,750			$	1,988			$	2,908
Basic net income per share:
Net income		$	0.25			$	0.45			$	0.54			$	0.75
Diluted net income per share:
Net income		$	0.25			$	0.44			$	0.53			$	0.72
Weighted average common shares outstanding:
Basic			3,657				3,861				3,654				3,856
Diluted			3,767				4,012				3,774				4,014
Common shares outstanding			3,642				3,861				3,642				3,861

SOURCE: Pro-Dex, Inc.

View source version on accesswire.com:
https://www.accesswire.com/687039/Pro-Dex-Inc-Announces-Fiscal-2022-Second-Quarter-and-Six-Month-Results

FAQ

What were Pro-Dex's financial results for Q2 2022?

Pro-Dex reported Q2 2022 net sales of $10.2 million, a 23% increase from Q2 2021, with a gross profit of $3.4 million.

How did Pro-Dex's net income change in Q2 2022?

Net income for Q2 2022 was $925,000, down from $1.8 million in the same quarter last year.

What challenges does Pro-Dex anticipate for upcoming quarters?

Pro-Dex expects supply chain challenges to negatively impact net sales in Q3 and Q4 2022.

What is the outlook for Pro-Dex's financial performance?

Despite short-term supply chain issues, Pro-Dex remains optimistic about its long-term growth prospects.